Clinical Trial Update: Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing safety, efficacy, and pharmacokinetics of leuprolide mesylate (LMIS 25 mg) in subjects with prostate cancer; results completed an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer
• Prostatic Neoplasms

Drugs mentioned

• Leuprolide mesylate (LMIS 25 mg) (leuprolide mesylate)

Snippet

Sponsor: Foresee Pharmaceuticals Co., Ltd. | Conditions: Prostatic Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2020-05-04